EN DE
Watch LAUNXP Biomedical Co., Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

LAUNXP Biomedical Co., Ltd (6876) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of LAUNXP Biomedical Co., Ltd stock NT$1.08, price NT$12.00, that is 91.0% below the price, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006876006

LB LAUNXP Biomedical Co., Ltd logo Thin data Nov 21, 2026

LAUNXP Biomedical Co., Ltd

6876 · TWO

Far too expensive (fair value 91% below the price) and weak company.

Follow free in the weekly email
Mixed Growth (revenue YoY +22481.8 %/yr in TWD) 
Fair value NT$1.08 · Strongly overvalued 
Quality 32/100 
Negative free cash flow 
Trails peers (1/4) 
Narrow moat 23/100
Thin data 
⚠ Dilution
Watch LAUNXP Biomedical Co., Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

NT$25.10 NT$9.77 Fair Value NT$1.08 Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

12‑month range NT$9.77 – NT$25.10 · fair‑value band NT$0.714 – NT$1.35 · the NT$12.00 price screens above the NT$1.08 fair value. As of Nov 21, 2026.

Follow LAUNXP Biomedical Co. in your weekly email

Every Wednesday you see whether LAUNXP Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients.

Show moreShow less

It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment.

The company was founded in 2015 and is based in Taichung, Taiwan.

Stock analysis

LAUNXP Biomedical Co., Ltd (6876) currently trades at NT$12.00, while our model-based Fair Value estimate is NT$1.08, 91% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.

Scenario range: NT$0.714 (bear) to NT$1.35 (bull), the price of NT$12.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

LAUNXP Biomedical Co., Ltd reported revenue of 2.5M TWD in FY2024 versus 0 TWD in FY2021. Reported net income was −82.6M TWD in FY2024.

Key figures

Market cap 991M TWD (≈ $30.1M) Micro · EPS (TTM) NT$-7.83 · Return on assets (EBIT) −71.8% (4-year average) · Free cash flow −77.0M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 52% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −91%, 6876 screens richer than that median.

Fair Value models

Bear NT$0.714 Fair Value NT$1.08 Bull NT$1.35
Price NT$12.00 · Downside -91.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) NT$0.8400 NT$1.27 NT$1.59 52
All 1 models by family
Asset-Based
NCAV (Graham) NT$0.8400 NT$1.27 NT$1.59 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 52
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 18
Does it invest with discipline instead of growing at any price?
Low Volatility 2
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

6876 screens overvalued: fair value 91% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare LAUNXP Biomedical Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Below median
Fair Value upside −91.0% · Bottom 25%
Profitability
Return on assets −66.7% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.28× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs 6876
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs 6876
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs 6876
argenx SE ARGX $925.70 $908.40 −2% vs 6876
CSL Limited CSL A$197.29 A$188.80 −4% vs 6876
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs 6876
Moderna, Inc MRNA $195.00 $119.97 −38% vs 6876
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs 6876
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs 6876
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs 6876

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LAUNXP Biomedical Co., Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "LAUNXP Biomedical Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6876

Frequently asked questions

Is LAUNXP Biomedical Co., Ltd (6876) overvalued or undervalued?
As of Nov 21, 2026, our model estimates a fair value of NT$1.08 versus a price of NT$12.00, about 91% lower (overvalued).
What is the fair value of 6876?
Our model-based fair value for LAUNXP Biomedical Co., Ltd is NT$1.08 (as of Nov 21, 2026), built from audited fundamentals. The current price: NT$12.00.
What is the quality score of 6876?
LAUNXP Biomedical Co., Ltd has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LAUNXP Biomedical Co., Ltd (6876)?
We do not set a price target; the yardstick is the fair value of NT$1.08 (as of Nov 21, 2026) from 1 valuation models. Cautious scenario NT$0.714, optimistic scenario NT$1.35. It is a calculation from audited fundamentals, not an analyst target.
What is the LAUNXP Biomedical Co., Ltd stock forecast for 2026?
Our models put fair value at NT$1.08, about 91% lower versus a price of NT$12.00 (overvalued). Cautious scenario NT$0.714, optimistic scenario NT$1.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of LAUNXP Biomedical Co., Ltd (6876)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LAUNXP Biomedical Co., Ltd it is NT$1.08 per share (as of Nov 21, 2026), against a price of NT$12.00. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is LAUNXP Biomedical Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 21, 2026, 6876 trades above its calculated fair value: price NT$12.00, fair value NT$1.08, a gap of about −91% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6876?
No. The price is what the market pays today (NT$12.00); the fair value is what the company's own numbers justify (NT$1.08). For LAUNXP Biomedical Co., Ltd the two are NT$10.92 per share apart. That gap is exactly why we show both numbers side by side.
How much is LAUNXP Biomedical Co., Ltd worth?
The market values LAUNXP Biomedical Co., Ltd at about 991M TWD (market capitalisation, as of Nov 21, 2026). Per share that is NT$12.00; our models calculate a fair value of NT$1.08 per share.
What do the bullish and bearish scenarios say about 6876?
Our models span a range for LAUNXP Biomedical Co., Ltd: cautious scenario NT$0.714, base NT$1.08, optimistic NT$1.35 per share (as of Nov 21, 2026, price NT$12.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 6876 from its 52-week high?
LAUNXP Biomedical Co., Ltd trades at NT$12.00, about 52% below its 52-week high of NT$25.10 and 23% above the low of NT$9.77 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of NT$1.08 is for.
Which stocks are comparable to LAUNXP Biomedical Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LAUNXP Biomedical Co., Ltd stock attractive at the current price?
The data as of Nov 21, 2026: price NT$12.00, calculated fair value NT$1.08 (−91%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6876 calculated?
We run LAUNXP Biomedical Co., Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of NT$1.08 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. LAUNXP Biomedical Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LAUNXP Biomedical Co., Ltd (6876)?
The closing price on Nov 20, 2026 was NT$12.00. Our model-based fair value is NT$1.08, about 91% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LAUNXP Biomedical Co., Ltd right now?
The price sits above even our optimistic bull case (NT$1.35). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (NT$0.714 to NT$1.35) leaves room in how you read the outcome.

Key figures of LAUNXP Biomedical Co., Ltd

How large is the market capitalisation of LAUNXP Biomedical Co., Ltd (6876)?
The market capitalisation of LAUNXP Biomedical Co., Ltd is 991M TWD (≈ $30.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of LAUNXP Biomedical Co., Ltd (6876)?
Earnings per share at LAUNXP Biomedical Co., Ltd are NT$-7.83. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of LAUNXP Biomedical Co., Ltd (6876)?
On an EBIT basis the return on assets of LAUNXP Biomedical Co., Ltd is −71.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does LAUNXP Biomedical Co., Ltd (6876) generate?
The free cash flow of LAUNXP Biomedical Co., Ltd is −77.0M TWD (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch LAUNXP Biomedical Co., Ltd in the live analysis

One click puts LAUNXP Biomedical Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.